Ubiquitin-specific protease 22 is a deubiquitinase of CCNB1

Cell Discovery

Volumn 1, Issue , 2015, Pages

  Lin, Zhenghong ^a,c   Tan, Can ^a   Qiu, Quan ^a   Kong, Sinyi ^a   Yang, Heeyoung ^a,d   Zhao, Fang ^a   Liu, Zhaojian ^a   Li, Jinping ^a   Kong, Qingfei ^a   Gao, Beixue ^a   Barrett, Terry ^a   Yang, Guang Yu ^a   Zhang, Jianing ^b   Fang, Deyu ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^c CHONGQING UNIVERSITY   (China)

^d Korea Institute of Toxicology   (South Korea)

Author keywords

APC8; CCNB1; cell cycle; tumorigenesis; USP22

Indexed keywords

ANAPHASE PROMOTING COMPLEX; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN E; DEUBIQUITINASE; HISTONE H3; MESSENGER RNA; PROTEASOME; UBIQUITIN SPECIFIC PROTEASE 22; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; TUMOR VOLUME; UBIQUITINATION; UPREGULATION;

EID: 84979686783     PISSN: None     EISSN: 20565968     Source Type: Journal    
DOI: 10.1038/celldisc.2015.28     Document Type: Article

References (65)

1. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-2460.
2. Glinsky GV. Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell cycle 2006; 5: 1208-1216.
3. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005; 115: 1503-1521.
4. Santos SD, Wollman R, Meyer T, Ferrell JE Jr. Spatial positive feedback at the onset of mitosis. Cell 2012; 149: 1500-1513.
5. Nixon VL, Levasseur M, McDougall A, Jones KT. Ca(2+) oscillations promote APC/C-dependent cyclin B1 degradation during metaphase arrest and completion of meiosis in fertilizing mouse eggs. Curr Biol 2002; 12: 746-750.
6. Gong D, Ferrell JE Jr. The roles of cyclin A2, B1, and B2 in early and late mitotic events. Mol Biol Cell 2010; 21: 3149-3161.
7. Bondi J, Husdal A, Bukholm G, Nesland JM, Bakka A, Bukholm IR. Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome. J Clin Pathol 2005; 58: 509-514.
8. Wang A, Yoshimi N, Ino N, Tanaka T, Mori H. Overexpression of cyclin B1 in human colorectal cancers. J Cancer Res Clin Oncol 1997; 123: 124-127.
9. Wang Q, Moyret-Lalle C, Couzon F et al. Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene 2003; 22: 1486-1490.
10. Zhao M, Kim YT, Yoon BS et al. Expression profiling of cyclin B1 and D1 in cervical carcinoma. Exp Oncol 2006; 28: 44-48.
11. Ikuerowo SO, Kuczyk MA, Mengel M et al. Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients. Int J Cancer 2006; 119: 867-874.
12. Heald R, McLoughlin M, McKeon F. Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase. Cell 1993; 74: 463-474.
13. Fotedar R, Flatt J, Gupta S et al. Activation-induced T-cell death is cell cycle dependent and regulated by cyclin B. Mol Cell Biol 1995; 15: 932-942.
14. Sarafan-Vasseur N, Lamy A, Bourguignon J et al. Overexpression of B-type cyclins alters chromosomal segregation. Oncogene 2002; 21: 2051-2057.
15. Lee KK, Florens L, Swanson SK, Washburn MP, Workman JL. The deubiquitylation activity of Ubp8 is dependent upon Sgf11 and its association with the SAGA complex. Mol Cell Biol 2005; 25: 1173-1182.
16. Samara NL, Datta AB, Berndsen CE et al. Structural insights into the assembly and function of the SAGA deubiquitinating module. Science 2010; 328: 1025-1029.
17. Kohler A, Zimmerman E, Schneider M, Hurt E, Zheng N. Structural basis for assembly and activation of the heterotetrameric SAGA histone H2B deubiquitinase module. Cell 2010; 141: 606-617.
18. Armour SM, Bennett EJ, Braun CR et al. A highconfidence interaction map identifies SIRT1 as a mediator of acetylation of USP22 and the SAGA coactivator complex. Mol Cell Biol 2013; 33: 1487-1502.
19. Xiong J, Wang Y, Gong Z, Liu J, Li W. Identification of a functional nuclear localization signal within the human USP22 protein. Biochem Biophys Res Commun 2014; 449: 14-18.
20. Sussman RT, Stanek TJ, Esteso P, Gearhart JD, Knudsen KE, McMahon SB. The epigenetic modifier ubiquitin-specific protease 22 (USP22) regulates embryonic stem cell differentiation via transcriptional repression of sex-determining region Y-box 2 (SOX2). J Biol Chem 2013; 288: 24234-24246.
21. Zhao Y, Lang G, Ito S et al. A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell 2008; 29: 92-101.
22. Zhang XY, Varthi M, Sykes SM et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell 2008; 29: 102-111.
23. Atanassov BS, Evrard YA, Multani AS et al. Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance. Mol Cell 2009; 35: 352-364.
24. Lang G, Bonnet J, Umlauf D et al. The tightly controlled deubiquitination activity of the human SAGA complex differentially modifies distinct gene regulatory elements. Mol Cell Biol 2011; 31: 3734-3744.
25. Lin Z, Yang H, Kong Q et al. USP22 Antagonizes p53 Transcriptional Activation by Deubiquitinating Sirt1 to Suppress Cell Apoptosis and Is Required for Mouse Embryonic Development. Mol cell 2012; 46: 484-494.
26. Liu YL, Yang YM, Xu H, Dong XS. Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer. J Surg Oncol 2011; 103: 283-289.
27. Izawa D, Pines J. How APC/C-Cdc20 changes its substrate specificity in mitosis. Nat Cell Biol 2011; 13: 223-233.
28. Porter LA, Cukier IH, Lee JM. Nuclear localization of cyclin B1 regulates DNA damage-induced apoptosis. Blood 2003; 101: 1928-1933.
29. Minshull J, Golsteyn R, Hill CS, Hunt T. The A- and B-type cyclin associated cdc2 kinases in Xenopus turn on and off at different times in the cell cycle. EMBO J 1990; 9: 2865-2875.
30. Clute P, Pines J. Temporal and spatial control of cyclin B1 destruction in metaphase. Nat Cell Biol 1999; 1: 82-87.
31. Zhang Y, Wang Z, Liu DX, Pagano M, Ravid K. Ubiquitin-dependent degradation of cyclin B is accelerated in polyploid megakaryocytes. J Biol Chem 1998; 273: 1387-1392.
32. Dimova NV, Hathaway NA, Lee BH et al. APC/C-mediated multiple monoubiquitylation provides an alternative degradation signal for cyclin B1. Nat Cell Biol 2012; 14: 168-176.
33. Huang X, Summers MK, Pham V et al. Deubiquitinase USP37 is activated by CDK2 to antagonize APC(CDH1) and promote S phase entry. Mol Cell 2011; 42: 511-523.
34. Wei Y, Chen YH, Li LY et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol 2011; 13: 87-94.
35. Datta NS, Williams JL, Caldwell J, Curry AM, Ashcraft EK, Long MW. Novel alterations in CDK1/cyclin B1 kinase complex formation occur during the acquisition of a polyploid DNA content. Mol Biol Cell 1996; 7: 209-223.
36. Blondel M, Mann C. G2 cyclins are required for the degradation of G1 cyclins in yeast. Nature 1996; 384: 279-282.
37. Gupta M, Trott D, Porter AC. Rescue of a human cell line from endogenous Cdk1 depletion by Cdk1 lacking inhibitory phosphorylation sites. J Biol Chem 2007; 282: 4301-4309.
38. Sgarlata C, Perez-Martin J. Inhibitory phosphorylation of a mitotic cyclin-dependent kinase regulates the morphogenesis, cell size and virulence of the smut fungus Ustilago maydis. J Cell Sci 2005; 118: 3607-3622.
39. Hong KU, Kim HJ, Kim HS et al. Cdk1-cyclin B1-mediated phosphorylation of tumor-associated microtubule-associated protein/cytoskeleton-associated protein 2 in mitosis. J Biol Chem 2009; 284: 16501-16512.
40. Deibler RW, Kirschner MW. Quantitative reconstitution of mitotic CDK1 activation in somatic cell extracts. Mol Cell 2010; 37: 753-767.
41. Pagliuca FW, Collins MO, Lichawska A, Zegerman P, Choudhary JS, Pines J. Quantitative proteomics reveals the basis for the biochemical specificity of the cell-cycle machinery. Mol Cell 2011; 43: 406-417.
42. Chesnel F, Bazile F, Pascal A, Kubiak JZ. Cyclin B dissociation from CDK1 precedes its degradation upon MPF inactivation in mitotic extracts of Xenopus laevis embryos. Cell Cycle 2006; 5: 1687-1698.
43. Jin P, Hardy S, Morgan DO. Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol 1998; 141: 875-885.
44. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438-449.
45. Peters JM. The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol Cell 2002; 9: 931-943.
46. Kitagawa R, Law E, Tang L, Rose AM. The Cdc20 homolog, FZY-1, and its interacting protein, IFY-1, are required for proper chromosome segregation in Caenorhabditis elegans. Curr Biol 2002; 12: 2118-2123.
47. Acquaviva C, Herzog F, Kraft C, Pines J. The anaphase promoting complex/cyclosome is recruited to centromeres by the spindle assembly checkpoint. Nat Cell Biol 2004; 6: 892-898.
48. Yamano H, Tsurumi C, Gannon J, Hunt T. The role of the destruction box and its neighbouring lysine residues in cyclin B for anaphase ubiquitin-dependent proteolysis in fission yeast: defining the D-box receptor. EMBO J 1998; 17: 5670-5678.
49. Fang G, Yu H, Kirschner MW. Direct binding of CDC20 protein family members activates the anaphase-promoting complex in mitosis and G1. Mol Cell 1998; 2: 163-171.
50. Bentzien F, Struman I, Martini JF, Martial J, Weiner R. Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Res 2001; 61: 7356-7362.
51. Gelman MS, Ye XK, Stull R et al. Identification of cell surface and secreted proteins essential for tumor cell survival using a genetic suppressor element screen. Oncogene 2004; 23: 8158-8170.
52. Almeida MI, Nicoloso MS, Zeng L et al. Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells. Gastroenterology 2012; 142: 886-896 e889.
53. Clark-Langone KM, Sangli C, Krishnakumar J, Watson D. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay. BMC Cancer 2010; 10: 691.
54. O'Connell MJ, Lavery I, Yothers G et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010; 28: 3937-3944.
55. Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011; 29: 17-24.
56. Mettu RK, Wan YW, Habermann JK, Ried T, Guo NL. A 12-gene genomic instability signature predicts clinical outcomes in multiple cancer types. Int J Biol Markers 2010; 25: 219-228.
57. Glinsky GV. Death-from-cancer signatures and stem cell contribution to metastatic cancer. Cell Cycle 2005; 4: 1171-1175.
58. Chauhan D, Tian Z, Nicholson B et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 2012; 22: 345-358.
59. Reverdy C, Conrath S, Lopez R et al. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem Biol 2012; 19: 467-477.
60. Liu J, Xia H, Kim M et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 2011; 147: 223-234.
61. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006; 6: 369-381.
62. Yang Q, Ferrell JE Jr. The Cdk1-APC/C cell cycle oscillator circuit functions as a time-delayed, ultrasensitive switch. Nat Cell Biol 2013; 15: 519-525.
63. Luo J, Nikolaev AY, Imai S et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107: 137-148.
64. Atanassov BS, Dent SY. USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep 2011; 12: 924-930.
65. Shan J, Zhao W, Gu W. Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol Cell 2009; 36: 469-476.